Tech Company Financing Transactions
Fortuna Fix Funding Round
Amgen Ventures and private investors invested in a $25 million Series B funding round for Fortuna Fix. The financing round was announced on 11/9/2017.
Transaction Overview
Company Name
Announced On
11/9/2017
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series B
Investors
Amgen Ventures (John Dunlop)
Proceeds Purpose
The proceeds will enable the company to conduct Phase I/IIa clinical trials in Parkinson's Disease and Spinal Cord Injury.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
500 Cartier Blvd. West 133
Laval QC, H7R 1C4
Canada
Laval QC, H7R 1C4
Canada
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Fortuna Fix is a private, clinical-stage biotech company with a patented direct cell reprogramming technology platform (drNPC) and a proprietary bio-scaffolding technology (RMx), for the treatment of neurodegenerative diseases and neurotrauma.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Thomas Eide
Chief Executive Officer
Jan-Eric Ahlfors
Chief Financial Officer
Vikram Lamba
VP - Bus. Development
Allyson Gage
VP - Bus. Development
Masha Gris
VP - Regulatory Affairs
Alice Varga
Browse more venture capital transactions:
Prev: 11/9/2017: TrackStreet venture capital transaction
Next: 11/9/2017: AdvicePay venture capital transaction
Share this article
News on VC Transactions
We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs